Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

4,723 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Long-term outcome following imatinib therapy for chronic myelogenous leukemia, with assessment of dosage and blood levels: the JALSG CML202 study.
Ohnishi K, Nakaseko C, Takeuchi J, Fujisawa S, Nagai T, Yamazaki H, Tauchi T, Imai K, Mori N, Yagasaki F, Maeda Y, Usui N, Miyazaki Y, Miyamura K, Kiyoi H, Ohtake S, Naoe T; Japan Adult Leukemia Study Group. Ohnishi K, et al. Among authors: maeda y. Cancer Sci. 2012 Jun;103(6):1071-8. doi: 10.1111/j.1349-7006.2012.02253.x. Epub 2012 Apr 16. Cancer Sci. 2012. PMID: 22364419 Free PMC article. Clinical Trial.
Nilotinib as frontline therapy for patients with newly diagnosed Ph+ chronic myeloid leukemia in chronic phase: results from the Japanese subgroup of ENESTnd.
Nakamae H, Shibayama H, Kurokawa M, Fukuda T, Nakaseko C, Kanda Y, Nagai T, Ohnishi K, Maeda Y, Matsuda A, Amagasaki T, Yanada M. Nakamae H, et al. Among authors: maeda y. Int J Hematol. 2011 May;93(5):624-632. doi: 10.1007/s12185-011-0841-8. Epub 2011 Apr 27. Int J Hematol. 2011. PMID: 21523338 Clinical Trial.
A Phase I/II study of nilotinib in Japanese patients with imatinib-resistant or -intolerant Ph+ CML or relapsed/refractory Ph+ ALL.
Tojo A, Usuki K, Urabe A, Maeda Y, Kobayashi Y, Jinnai I, Ohyashiki K, Nishimura M, Kawaguchi T, Tanaka H, Miyamura K, Miyazaki Y, Hughes T, Branford S, Okamoto S, Ishikawa J, Okada M, Usui N, Tanii H, Amagasaki T, Natori H, Naoe T. Tojo A, et al. Among authors: maeda y. Int J Hematol. 2009 Jun;89(5):679-88. doi: 10.1007/s12185-009-0327-0. Epub 2009 May 19. Int J Hematol. 2009. PMID: 19449194 Clinical Trial.
Randomized trial of response-oriented individualized versus fixed-schedule induction chemotherapy with idarubicin and cytarabine in adult acute myeloid leukemia: the JALSG AML95 study.
Ohtake S, Miyawaki S, Kiyoi H, Miyazaki Y, Okumura H, Matsuda S, Nagai T, Kishimoto Y, Okada M, Takahashi M, Handa H, Takeuchi J, Kageyama S, Asou N, Yagasaki F, Maeda Y, Ohnishi K, Naoe T, Ohno R. Ohtake S, et al. Among authors: maeda y. Int J Hematol. 2010 Mar;91(2):276-83. doi: 10.1007/s12185-009-0480-5. Int J Hematol. 2010. PMID: 20054669 Clinical Trial.
Intensified consolidation therapy with dose-escalated doxorubicin did not improve the prognosis of adults with acute lymphoblastic leukemia: the JALSG-ALL97 study.
Jinnai I, Sakura T, Tsuzuki M, Maeda Y, Usui N, Kato M, Okumura H, Kyo T, Ueda Y, Kishimoto Y, Yagasaki F, Tsuboi K, Horiike S, Takeuchi J, Iwanaga M, Miyazaki Y, Miyawaki S, Ohnishi K, Naoe T, Ohno R. Jinnai I, et al. Among authors: maeda y. Int J Hematol. 2010 Oct;92(3):490-502. doi: 10.1007/s12185-010-0672-z. Epub 2010 Sep 10. Int J Hematol. 2010. PMID: 20830614 Clinical Trial.
Discontinuation of imatinib in Japanese patients with chronic myeloid leukemia.
Takahashi N, Kyo T, Maeda Y, Sugihara T, Usuki K, Kawaguchi T, Usui N, Okamoto S, Ohe Y, Ohtake S, Kitamura K, Yamamoto M, Teshima H, Motoji T, Tamaki T, Sawada K, Ohyashiki K. Takahashi N, et al. Among authors: maeda y. Haematologica. 2012 Jun;97(6):903-6. doi: 10.3324/haematol.2011.056853. Epub 2011 Dec 16. Haematologica. 2012. PMID: 22180435 Free PMC article.
Efficacy and safety of nilotinib in Japanese patients with imatinib-resistant or -intolerant Ph+ CML or relapsed/refractory Ph+ ALL: a 36-month analysis of a phase I and II study.
Usuki K, Tojo A, Maeda Y, Kobayashi Y, Matsuda A, Ohyashiki K, Nakaseko C, Kawaguchi T, Tanaka H, Miyamura K, Miyazaki Y, Okamoto S, Oritani K, Okada M, Usui N, Nagai T, Amagasaki T, Wanajo A, Naoe T. Usuki K, et al. Among authors: maeda y. Int J Hematol. 2012 Apr;95(4):409-19. doi: 10.1007/s12185-012-1026-9. Epub 2012 Feb 23. Int J Hematol. 2012. PMID: 22359103 Clinical Trial.
Severe hemorrhagic complications during remission induction therapy for acute promyelocytic leukemia: incidence, risk factors, and influence on outcome.
Yanada M, Matsushita T, Asou N, Kishimoto Y, Tsuzuki M, Maeda Y, Horikawa K, Okada M, Ohtake S, Yagasaki F, Matsumoto T, Kimura Y, Shinagawa K, Iwanaga M, Miyazaki Y, Ohno R, Naoe T. Yanada M, et al. Among authors: maeda y. Eur J Haematol. 2007 Mar;78(3):213-9. doi: 10.1111/j.1600-0609.2006.00803.x. Epub 2007 Jan 16. Eur J Haematol. 2007. PMID: 17241371 Clinical Trial.
Feasibility of the imatinib stop study in the Japanese clinical setting: delightedly overcome CML expert stop TKI trial (DOMEST Trial).
Fujisawa S, Ueda Y, Usuki K, Kobayashi H, Kondo E, Doki N, Nakao T, Kanda Y, Kosugi N, Kosugi H, Kumagai T, Harada H, Shikami M, Maeda Y, Sakura T, Inokuchi K, Saito A, Nawa Y, Ogasawara M, Nishida J, Kondo T, Yoshida C, Kuroda H, Tabe Y, Maeda Y, Imajo K, Kojima K, Morita S, Komukai S, Kawaguchi A, Sakamoto J, Kimura S. Fujisawa S, et al. Among authors: maeda y. Int J Clin Oncol. 2019 Apr;24(4):445-453. doi: 10.1007/s10147-018-1368-2. Epub 2018 Nov 12. Int J Clin Oncol. 2019. PMID: 30421023 Free PMC article. Clinical Trial.
Final 3-year Results of the Dasatinib Discontinuation Trial in Patients With Chronic Myeloid Leukemia Who Received Dasatinib as a Second-line Treatment.
Okada M, Imagawa J, Tanaka H, Nakamae H, Hino M, Murai K, Ishida Y, Kumagai T, Sato S, Ohashi K, Sakamaki H, Wakita H, Uoshima N, Nakagawa Y, Minami Y, Ogasawara M, Takeoka T, Akasaka H, Utsumi T, Uike N, Sato T, Ando S, Usuki K, Mizuta S, Hashino S, Nomura T, Shikami M, Fukutani H, Ohe Y, Kosugi H, Shibayama H, Maeda Y, Fukushima T, Yamazaki H, Tsubaki K, Kukita T, Adachi Y, Nataduka T, Sakoda H, Yokoyama H, Okamoto T, Shirasugi Y, Onishi Y, Nohgawa M, Yoshihara S, Morita S, Sakamoto J, Kimura S; DADI Trial Group, Japan. Okada M, et al. Among authors: maeda y. Clin Lymphoma Myeloma Leuk. 2018 May;18(5):353-360.e1. doi: 10.1016/j.clml.2018.03.004. Epub 2018 Mar 15. Clin Lymphoma Myeloma Leuk. 2018. PMID: 29610029 Free article. Clinical Trial.
4,723 results